Advertisement

The Design and Synthesis of Selective Prostaglandin Analogs As Bone Anabolic Agents for the Potential Treatment of Osteoporosis

  • David Lindsey Soper
  • Yili Wang
  • Biswanath De
  • Mitchell Anthony deLong
  • Michelle Jeanine Dirr
  • Michele Elaine Soehner
  • Mark Walden Lundy
  • Glen Edward Mieling
  • John August Wos
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 507)

Abstract

A series of prostaglandins selective for the human FP receptor have been synthesized and evaluated as potential therapeutics for the treatment of osteoporosis. The compounds proved to be potent (nanomolar binding affinity) and selective (>100x) ligands for the human FP receptor in vitro, and increased bone volume in the ovariectomized rat in vivo.

Keywords

Selective Ligand Prostanoid Receptor Prostaglandin Receptor Increase Bone Volume Cortical Hyperostosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1)(a.
    Ueda, K.; Saito, S.; Najano, H.; Aoshima, M.; Yokata, M.; Muraoka, R.; Iwaya, T. Cortical hyperostosis following long-term administration of prostaglandin E-1 in infants with cyanotic congential heart disease. J. Pediatr. 1980, 97, 834–836.PubMedCrossRefGoogle Scholar
  2. b.
    Ueno, K.; Haba, T.; Woodbury, D.; Price, P.; Anderson, R.; Jee, W.S.S. The effects of prostaglandin E2 in rapidly growing rats: Depressed longitudinal and radial growth and increased metaphyseal hard tissue mass. Bone 1985, 6, 79–86.PubMedCrossRefGoogle Scholar
  3. c.
    Ma. Y.F.; Li, X. J.; Jee, W.S.S.; Mcosker J.; Liang, X.G.; Setterberg, R.; Chow, S.Y. Effects of prostaglandin E2 and Fla on the skeleton of osteopenic ovariectomized rats. Bone 1995, 17, 549–554.PubMedCrossRefGoogle Scholar
  4. d.
    Jee, W.S.S.; Ma, Y.F. The in vivo anabolic actions of prostaglandins in bone. Bone 1997, 21, 297–304.PubMedCrossRefGoogle Scholar
  5. e.
    Ke, H.Z.; Shen, V.W.; Qi, H.; Crawford, D.T.; Wu, D.D.; Liang, X.G.; Chidsey-Frink, K.L.; Pirie, C.M.; Simmons, H. A.; Thompson, D.D. Prostaglandin E2 increases bone strength in intact rats and ovariectomized rats with established osteoporosis. Bone 1998, 23, 249–255.PubMedCrossRefGoogle Scholar
  6. 2)(a.
    Negishi, M.; Sugimoto, Y.; Ichikawa, A. Molecular mechanism of diverse actions of prostanoid receptors. Biochim. Biophy. Acta 1995, 1259, 109–120.CrossRefGoogle Scholar
  7. b.
    Abramovitz, M.; Metters, K.M. Prostanoid Receptors. Ann. Rep. Med Chem. 1998, 33, 223–232.Google Scholar
  8. c.
    Ruel, R.; Lacombe, P.; Abramovitz, M.; Godbout, C.; Lamontagne, S.; Rochette, C.; Sawyer, N.; Stocco, R.; Tremblay, N.; Metters, K.; Labelle, M. New class of biphenylene dibenzazocinones as potent ligands for the human EP1 prostanoid receptor. Bioorganic Med. Chem. Lett. 1999, 9, 2699–2705.CrossRefGoogle Scholar
  9. 3.
    Wang, Y.; Wos, J. A.; Dirr, M. A.; Soper, D. L.; deLong, M. A.; Mieling, G.; De, B.; Amburgey, J; Suchanek, E. and Taylor, C. J. The design and synthesis of 13,14 - dihydro prostaglandin Fla analogs as potent and selective ligands for the human FP receptor. J. Med. Chem. 2000, in press.Google Scholar
  10. 4)(d.
    Hartke, J.R.; Jankowsky, M. L.; deLong, M. A.; Soehner, M. E.; Jee, W. S. S.; Lundy, M. W. Prostanoid FP agonists build bone in the ovariectomized rat. Journal Of Bone And Mineral Research 1999 Vol. 14, Suppl. 1, S207.Google Scholar
  11. e.
    DeLong, M. A.; Hartke, J. R.; Jankowsky, M. L.; Soehner, M. E.; Wos, J. A.; Soper, D. L; Lundy, M. W. Tetrahydro-fluprostenol, a 17-phenyl saturated prostanoid FP receptor agonist, is a bone anabolic agent in the aged, ovx rat. Journal Of Bone And Mineral Research 1999 Vo1.14, Suppl. 1, S275Google Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • David Lindsey Soper
    • 1
  • Yili Wang
    • 1
  • Biswanath De
    • 1
  • Mitchell Anthony deLong
    • 1
  • Michelle Jeanine Dirr
    • 1
  • Michele Elaine Soehner
    • 1
  • Mark Walden Lundy
    • 1
  • Glen Edward Mieling
    • 1
  • John August Wos
    • 1
  1. 1.Procter and Gamble PharmaceuticalsOhio

Personalised recommendations